Also listed in trial records as Actinomycin C1, Actinomycin I1
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our Canada, Australia, Israel, China and Mexico registers that name Dactinomycin as an intervention.Synced 27 Sep 2026
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards
At a glance
Dactinomycin is named as an intervention in 7 current clinical trials
in our Canada, Australia, Israel, China and Mexico registers.
4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Children's Oncology Group (5). The most-studied condition is Embryonal Rhabdomyosarcoma.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
NCT06401330 · ClinicalTrials.gov ↗ · Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
02
Conditions studied with Dactinomycin
16 conditions
Embryonal Rhabdomyosarcoma3Rhabdomyosarcoma2Alveolar Rhabdomyosarcoma2Botryoid-Type Embryonal Rhabdomyosarcoma2Gestational Trophoblastic Tumor1Gestational Trophoblastic Neoplasia1Stage I Gestational Trophoblastic Tumor1Stage II Gestational Trophoblastic Tumor1Pleuropulmonary Blastoma1Fusion-Negative Alveolar Rhabdomyosarcoma1Spindle Cell/Sclerosing Rhabdomyosarcoma1Stage I Mixed Cell Type Kidney Wilms Tumor1
How many clinical trials are testing Dactinomycin?
7 current trials in our Canada, Australia, Israel, China and Mexico registers name Dactinomycin (also registered as Actinomycin C1) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Are Dactinomycin trials recruiting patients?
Yes. 4 of the 7 trials are recruiting: 4 with sites in Canada, 2 with sites in Australia, 2 with sites in Israel and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Dactinomycin clinical trials?
Children's Oncology Group (5), xiang yang (1) and National Cancer Institute (NCI) (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dactinomycin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dactinomycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dactinomycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.
Please verify before you rely on this.
This page is general information for life-science and pharmaceutical professionals. It is
not medical advice, and it has not been reviewed by a clinician — our editorial
team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most
recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC)
and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not
automatically interchangeable, and approvals, brand names and indications differ between the US, the
EU/Ireland (EMA/HPRA) and other regions.
Spotted an error? Tell us — we correct promptly and log it.
We value your privacy
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.